<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03171987</url>
  </required_header>
  <id_info>
    <org_study_id>N201702048</org_study_id>
    <nct_id>NCT03171987</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of 5% Lidocaine Patch and Flurbiprofen Patch for Relieving Acute Low Back Pain</brief_title>
  <official_title>The Safety and Efficacy of 5% Lidocaine Patch and Flurbiprofen Patch for Relieving Acute Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Medical University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, single blinded, two-arm, head to head study.

      The purpose of this study is:

        -  To evaluate and compare the efficacy of 5% lidocaine patch and flurbiprofen patch for
           treatment of acute low back pain.

      Determining the effect of the 5% lidocaine patch and flurbiprofen patch for improving
      functional disabilities and in reducing pain resulting from acute low back pain. Efficacy
      will be determined by the level of pain relief (as measured by the Numerical Rating Scale,
      NRS), decrease in analgesics, improved quality of life (as measured by the Oswestry
      Disability Questionnaire, ODQ, and core outcome measures index questionnaire, COMI), pain
      interference with function (as measured by the Brief Pain Inventory-Interference scale,
      BPI-QoL), Short-Form McGill Pain Questionnaire-2(SF-MPQ-2), general health status (as
      measured by the EQ5D), Overall treatment effect (OTE), physical exam from baseline up to
      1-Months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Lidocaine patch group: 1 piece lidocaine patch per day at back pain area.
Flurbiprofen patch group: 1 piece flurbiprofen patch per day at back pain area. Treatment last for 28 days.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
    <masking_description>The investigator and care provider will be blind to group. Participant will know their treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Numeric rating scale (NRS)</measure>
    <time_frame>28 day</time_frame>
    <description>Back pain relief effectiveness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numeric rating scale (NRS)</measure>
    <time_frame>0, 1, 3, 7, 14, 21 day</time_frame>
    <description>Back pain relief effectiveness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory-Quality of Life (BPI-QoL)</measure>
    <time_frame>0, 7, 14, 21, 28 day</time_frame>
    <description>Back pain relief effectiveness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Questionnaire (ODQ)</measure>
    <time_frame>0, 7, 14, 21, 28 day</time_frame>
    <description>Back pain relief effectiveness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Core Outcome Measurement Index (COMI)</measure>
    <time_frame>0, 7, 14, 21, 28 day</time_frame>
    <description>Back pain relief effectiveness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ5D Quality of Life questionnaires Efficacy</measure>
    <time_frame>0, 7, 14, 21, 28 day</time_frame>
    <description>Back pain relief effectiveness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short form-Mcgill Pain Questionnaire (SF-MPQ-2)</measure>
    <time_frame>0, 7, 14, 21, 28 day</time_frame>
    <description>Back pain relief effectiveness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Treatment Effect Scale (OTE)</measure>
    <time_frame>7, 14, 21, 28 day</time_frame>
    <description>Back pain relief effectiveness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic consumption</measure>
    <time_frame>7, 14, 21, 28 day</time_frame>
    <description>Back pain relief effectiveness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin reaction grade (Assessment of dermal response)</measure>
    <time_frame>1, 3, 7, 14, 21, 28 days</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Common Terminology Criteria for Adverse Events (CTCAE)</measure>
    <time_frame>1, 3, 7, 14, 21, 28 days</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Physical exams for back range of motion</measure>
    <time_frame>0, 7, 14, 21, 28 day</time_frame>
    <description>Back pain relief effectiveness</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Acute Back Pain</condition>
  <arm_group>
    <arm_group_label>Lidocaine patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lidocaine patch local application 1 piece per day for 28 days at back pain area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flurbiprofen patch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Flurbiprofen patch local application 1 piece per day for 28 days at back pain area.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine patch local application</intervention_name>
    <description>Attach the patch to back pain area 1 piece per day with no more than 6 hours.</description>
    <arm_group_label>Lidocaine patch</arm_group_label>
    <other_name>Lidopat patch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flurbiprofen patch local application</intervention_name>
    <description>Attach the patch to back pain area 1 piece per day with no more than 6 hours.</description>
    <arm_group_label>Flurbiprofen patch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects underwent a detailed history and systemic physical examination including
             neurologic and musculoskeletal evaluations. To rule out any confounding etiologies,
             basic diagnostic laboratory tests including complete blood count and acute phase
             reactants (erythrocyte sedimentation rate and C-reactive protein) were performed. The
             patients diagnosed as having acute non-specific low back pain according to history and
             physical examinations were invited to participate and will be informed about the
             purpose and course of the study.

        Main inclusion criteria

          -  A primary complaint of pain in the area between the 12th rib and buttock crease
             without leg pain

          -  Female or male, 20 - 80 years of age

          -  Low back pain of less than six weeks' duration; and at least moderate pain intensity
             (NRS≧4)

        Exclusion Criteria:

        Main exclusion criteria:

          -  Known or suspected serious spinal pathology and spinal implants

          -  Lumbar spinal surgery within the preceding six months

          -  Serious comorbidities preventing prescription of paracetamol

          -  Alternative treatment for low back pain in previous two weeks

          -  Chronic neurological lesion

          -  Chronic musculoskeletal lesion

          -  Active cancer

          -  Pregnancy

          -  Use of pain medication (except paracetamol) within 3 days

          -  Treatment site has active skin lesion or inflammation

          -  Known allergy to skin patch
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ray-Jade Chen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Taipei Medical University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meng-Huang Wu, MD</last_name>
    <phone>+886227372181</phone>
    <phone_ext>3740</phone_ext>
    <email>maxwutmu@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shiao-Wei Ku, BS</last_name>
    <phone>+886227372181</phone>
    <phone_ext>3740</phone_ext>
    <email>weiwei820116@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jen-Yuh Chen</name>
      <address>
        <city>Taipei</city>
        <state>Please Select</state>
        <zip>11031</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JEN-YUH CHEN, MD</last_name>
      <phone>+8862395-6755</phone>
      <email>bonechen2010@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei</city>
        <state>Please Select</state>
        <zip>110</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meng-Huang Wu, MD</last_name>
      <phone>+886227372181</phone>
      <phone_ext>3740</phone_ext>
      <email>maxwutmu@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Shiao-Wei Ku, BS</last_name>
      <phone>+886227372181</phone>
      <phone_ext>3740</phone_ext>
      <email>weiwei820116@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Meng-Huang Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Coste J, Lefrançois G, Guillemin F, Pouchot J; French Study Group for Quality of Life in Rheumatology. Prognosis and quality of life in patients with acute low back pain: insights from a comprehensive inception cohort study. Arthritis Rheum. 2004 Apr 15;51(2):168-76.</citation>
    <PMID>15077256</PMID>
  </reference>
  <reference>
    <citation>Mick G, Correa-Illanes G. Topical pain management with the 5% lidocaine medicated plaster--a review. Curr Med Res Opin. 2012 Jun;28(6):937-51. doi: 10.1185/03007995.2012.690339. Epub 2012 May 24. Review.</citation>
    <PMID>22551228</PMID>
  </reference>
  <reference>
    <citation>Bolten W. The pharmacokinetics, pharmacodynamics and comparative efficacy of flurbiprofen LAT. Br J Clin Pract. 1994 Jul-Aug;48(4):190-5.</citation>
    <PMID>7917798</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2017</study_first_submitted>
  <study_first_submitted_qc>May 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2017</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taipei Medical University Hospital</investigator_affiliation>
    <investigator_full_name>Meng-Huang Wu</investigator_full_name>
    <investigator_title>Orthopedic specialist</investigator_title>
  </responsible_party>
  <keyword>lidocaine patch</keyword>
  <keyword>flurbiprofen patch</keyword>
  <keyword>acute back pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Flurbiprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No shore IPD plan.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

